ALK and non-small cell lung carcinoma: Crizotinib, a multi-targeted TKI with activity against c-Met and ALK, has been considered as the first-line treatment for ALK-rearranged advanced NSCLC patients with remarkable response in a series of clinical trials [37–40] .The objective response rate (ORR) and median progression free survival (PFS) of crizotinib were 74% and 10.9 months in ALK-rearranged patients, compared with 45% and 7.0 months of chemotherapy respectively [39].